Bone Bank Allografts Announces Partnership Capstone Health Alliance

Agreement provides 25,000 non-acute health care members high-quality orthobiologics

SAN ANTONIO, April 27, 2021 (GLOBE NEWSWIRE) -- Bone Bank Allografts (BBA), a leading provider of regenerative medicine technologies to the surgical community, announced a multi-year supplier partner agreement with Capstone Health Alliance, a regional group purchasing organization (GPO) with 300 hospitals representing 140 health systems across the United States. The agreement covers BBA’s comprehensive portfolio of orthobiologics that include surgical allograft options from traditional bone and soft tissues to specialty custom products for transplant.

“We are excited about our new long-term partnership with Capstone Health Alliance as their members now have greater access to high-quality solutions that address hospital and surgeon needs at a lower total cost of care today as well as moving forward,” said Chris Gould, Sr. Director of National Accounts at BBA.

With this expansion, BBA is seeking distributors and independent sales agents who are looking for the opportunity to sell orthobiologics to hospitals and surgeons. Interested parties are encouraged to request a meeting with BBA leadership by submitting a meeting request form at

About Bone Bank Allografts (BBA)
Located in San Antonio, Texas, BBA is leading provider of regenerative medicine technologies to the surgical community. Utilized in over 1 million successful transplantations since 1993, BBA is dedicated to maximizing the gift of donations by developing solutions that promote healing and recovery. BBA is accredited by the American Association of Tissue Banks (AATB), registered with the U.S. Food and Drug Administration (FDA) and in compliance with the FDA’s Good Tissue Practices. Visit to learn more.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

BBA Contact:
Chris Gould
Sr. Director of National Accounts